391 related articles for article (PubMed ID: 15336441)
1. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
2. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
4. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
6. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
7. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
[TBL] [Abstract][Full Text] [Related]
8. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
[TBL] [Abstract][Full Text] [Related]
9. Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice.
Kim HJ; Lee KT; Park YB; Jeon SM; Choi MS
Mol Nutr Food Res; 2008 Aug; 52(8):965-73. PubMed ID: 18481331
[TBL] [Abstract][Full Text] [Related]
10. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse.
Brix AE; Elgavish A; Nagy TR; Gower BA; Rhead WJ; Wood PA
Mol Genet Metab; 2002 Mar; 75(3):219-26. PubMed ID: 11914033
[TBL] [Abstract][Full Text] [Related]
12. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
13. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
[TBL] [Abstract][Full Text] [Related]
15. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice.
Pinto Lde F; Compri CM; Fornari JV; Bartchewsky W; Cintra DE; Trevisan M; Carvalho Pde O; Ribeiro ML; Velloso LA; Saad MJ; Pedrazzoli J; Gambero A
Liver Int; 2010 Apr; 30(4):603-10. PubMed ID: 20088867
[TBL] [Abstract][Full Text] [Related]
16. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.
Bijl N; Sokolović M; Vrins C; Langeveld M; Moerland PD; Ottenhoff R; van Roomen CP; Claessen N; Boot RG; Aten J; Groen AK; Aerts JM; van Eijk M
Hepatology; 2009 Nov; 50(5):1431-41. PubMed ID: 19731235
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
[TBL] [Abstract][Full Text] [Related]
19. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice.
Begriche K; Lettéron P; Abbey-Toby A; Vadrot N; Robin MA; Bado A; Pessayre D; Fromenty B
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E939-51. PubMed ID: 18349116
[TBL] [Abstract][Full Text] [Related]
20. Psammomys obesus (sand rat), a new animal model of non-alcoholic fatty liver disease.
Maislos M; Medvedovskv V; Sztarkier I; Yaari A; Sikuler E
Diabetes Res Clin Pract; 2006 Apr; 72(1):1-5. PubMed ID: 16242203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
